Insider Selling: Foundation Medicine Inc (FMI) CFO Sells 503 Shares of Stock

Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 503 shares of Foundation Medicine stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $34.55, for a total transaction of $17,378.65. Following the completion of the sale, the chief financial officer now directly owns 51,244 shares of the company’s stock, valued at $1,770,480.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jason Ryan also recently made the following trade(s):

  • On Thursday, March 16th, Jason Ryan sold 12,500 shares of Foundation Medicine stock. The shares were sold at an average price of $31.68, for a total transaction of $396,000.00.

Foundation Medicine Inc (NASDAQ:FMI) opened at 37.30 on Friday. Foundation Medicine Inc has a 12-month low of $16.95 and a 12-month high of $38.24. The stock’s market capitalization is $1.33 billion. The company’s 50-day moving average is $33.59 and its 200 day moving average is $25.81.

Foundation Medicine (NASDAQ:FMI) last announced its earnings results on Tuesday, May 9th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by $0.29. Foundation Medicine had a negative net margin of 84.67% and a negative return on equity of 42.21%. The firm had revenue of $26.32 million for the quarter, compared to analysts’ expectations of $29.07 million. During the same quarter last year, the business earned ($0.50) earnings per share. The business’s revenue was down 13.3% compared to the same quarter last year. On average, equities research analysts expect that Foundation Medicine Inc will post ($4.37) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/05/20/insider-selling-foundation-medicine-inc-fmi-cfo-sells-503-shares-of-stock-updated-updated-updated.html.

Several research firms have recently commented on FMI. Zacks Investment Research raised shares of Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Thursday, March 9th. BTIG Research raised shares of Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 target price for the company in a research report on Monday, May 15th. William Blair reissued a “buy” rating on shares of Foundation Medicine in a research report on Monday, April 3rd. Finally, Janney Montgomery Scott raised shares of Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 target price for the company in a research report on Tuesday, March 7th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $30.25.

Several institutional investors have recently made changes to their positions in the stock. Gilder Gagnon Howe & Co. LLC boosted its position in shares of Foundation Medicine by 0.5% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 1,610,865 shares of the company’s stock valued at $51,950,000 after buying an additional 7,347 shares during the last quarter. Discovery Group I LLC boosted its position in shares of Foundation Medicine by 2.3% in the fourth quarter. Discovery Group I LLC now owns 1,596,818 shares of the company’s stock valued at $28,264,000 after buying an additional 36,204 shares during the last quarter. Chevy Chase Trust Holdings Inc. boosted its position in shares of Foundation Medicine by 16.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 1,096,489 shares of the company’s stock valued at $35,362,000 after buying an additional 154,168 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Foundation Medicine by 38.7% in the first quarter. Alliancebernstein L.P. now owns 788,860 shares of the company’s stock valued at $25,441,000 after buying an additional 220,236 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in shares of Foundation Medicine by 7.0% in the third quarter. Oppenheimer & Co. Inc. now owns 721,271 shares of the company’s stock valued at $16,842,000 after buying an additional 47,350 shares during the last quarter. Institutional investors and hedge funds own 31.44% of the company’s stock.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

12 Month Chart for NASDAQ:FMI

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply